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Kokosanolide A (1), from the seeds of Lansium domesticum Corr. cv Kokossan, has been  shown strong 
cytotoxic activities (IC50 = 8.62 μg/mL) against MCF-7 breast cancer cells. The aim of this work was to study the 
molecular interactions of kokosanolid A and kokosanolid C with the Estrogen Receptor α (ERα) using computer 
aided drug design approaches. Molecular docking using Autodock Vina (open-source software PyRx 0.8) was 
employed to explore the modes of binding of  kokosanolid A (1) and kokosanolid C (2) with ERα. Compound 1 
and 2 showed strong bond-free energy (-8.8 kcal/mol and -8.7 kcal/mol) to ERα. These two compounds have 
molecular mechanism to inhibit ERα in breast cancer cells.   
 





1. INTRODUCTION  
Breast cancer is a disease in which 
cell growth is abnormal cell growth or 
uncontrolled. (Novianti & Purnami, 2012). 
There are various risk factors of breast cancer. 
Some of them are regarded as non-modifiable 
risk factors and the others are regarded as 
modifiable ones. The former includes, such as 
age, mutations in the BRCA1 and BRCA2 
genes, family history, reproductive history, 
and being exposed to high radiation to the 
chest. The latter are contributed by having, 
such as high endogenous estrogen, hormone 
therapy, obesity, and alcohol consumption.  
However, until now the effect of estrogen on 
breast cancer has attracted a lot of attention. 
This is due to its important role in causing 
breast cancer (Samavat & Kurzer, 2015). 
About 70% of breast cancers express estrogen 
receptor (ER) (Qi et al., 2011). Inhibiting the 
receptor activities can be a strategy in the 
treatment of estrogen receptor-positive breast 
cancer, either by inhibiting estrogen 
production using aromatase inhibitors or by 
interfering with the binding site of estrogen 
using selective estrogen receptor modulators 
(SERMs) (Belev & Vrbanec, 2012). Estrogen 
receptors belong to the nuclear receptor 
family and have two subtypes, namely 
estrogen receptor alpha (ERα) and beta (ERβ). 
From these two subtypes, 78% of breast 
cancers express ERα receptors making it the 
most important predictor for breast cancer 
prognosis (Burns & Korach, 2012).  
Current cancer research trends focus 
on developing anticancer drugs using natural 
compounds. Several methods such as in vitro, 
in vivo, and computation are used to see the 
potential of the drug. Molecular Docking has 
been used extensively in the prediction and 
design of drugs for cancer (Tabassum et al., 
2014; Zahra et al., 2013). Investigating 
bioactive compounds derived from medicinal 
plants lies in their affordability and 
convenience to increase efficacy and 
minimize serious side effects (Sudha et al., 
2018). Two tetranortriterpenoids, kokosanolid 
A and C have been reported found in the 
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seeds of L. domesticum Corr. Cv kokossan 
(Mayanti et al., 2011). Kokosanolid A , have 
been  shown to have strong cytotoxic activity 
(IC50 = 8.62 μg/mL) against MCF-7 breast 
cancer cells (Mayanti et al., 2016). L. 
domesticum is a tropical plant that is 
widespread in Asian regions such as 
Malaysia, Thailand, Indonesia, and the 
Philippines (Lim, 2012). Several previous 
reports have described the interesting 
bioactivity of triterpenoids came from L. 
domesticum, such as antimalarial (Saewan et 
al., 2006), insecticide (Leatemia & Isman, 
2004), antifeedant (Mayanti et al., 2011), 
antibacterial (Ragasa et al., 2006), 
antimutagenic (Matsumoto et al., 2018; 
Matsumoto et al., 2019), and anticancer 
activity (Fadhilah et al., 2020). In this paper, 
we report a study about interactions and 
potential activity of two tetranortriterpenoids, 
kokosanolide A (1) and kokosanolide C (2) 
(Figure 1) to inhibit ERα in breast cancer 
cells. 
 
Figure 1. Structures of Compounds 1 and 2 
2. MATERIAL AND METHODS  
Molecular Docking Assay 
ER-α (protein data bank ID: 3ERT) 
was used in this research for screening 
compound mechanism against breast cancer 
cells activity. The 3-dimensional structures 
were retrieved from RSCB Protein Data Bank 
(https://www.rcsb.org/) obtained in PDB 
format. Afimoxifene (4-OHT) was used as a 
positive control ligand and estradiol ligand for 
comparison. The 3D structures of the 
compounds were modeled by using Biovia 
Discovery Studio program (Mukund et al., 
2019). 
Autodock Vina (open-source software 
PyRx 0.8) was used for the ligand-protein 
docking and virtual screening for anticancer 
activity of the compounds. Compound 1, 
compound 2, 4-OHT, and estradiol were 
subjects for binding to ER-α as protein target, 
the ligand was free for blind docking. Before 
the ligand is thetered to the receptor, it is 
necessary to identify the active pocked that 
binds to the receptor through grid parameters. 
The grid box was produced by redocking 
tamoxifen against ERα is x=30.282; y=1.1913; 
z=24.207 with a space volume of 40x40x40 
points. The conformation was selected based 
on binding energy, the one with the lowest 
binding affinity score. The docking simulation 
was performed at the center of the active side 
of the receptor with coordinates (x = 30.010, y 
= -1.913, and z = 24.207) selected. 
The docking results were visualized 
by using Biovia Discovery Studio program. 
Ligand-residue interaction and docking poses 
in the 3-dimension molecular picture were 
showed by the program. The docking pose of 
each protein-ligand complex was compared by 
looking at the side of the amino acid residue 
that binds the ligand. The similarity from 
ligation poses of compound 1 and 2, 4-OHT, 
and estradiol that bound on amino acid 
residues was determined and the relation of 
the docking pose of the ligands and protein 
targets  being studied was selected. Prediction 
of pharmacokinetics was carried out with a 
SMILE structure analyzed using swiss ADME 
http://www.swissadme.ch/index.php) (Daina 
et al., 2017). 
 
3. RESULTS AND DISCUSSIONS 
The molecular mechanism prediction 
of the compounds binding the ERα was 
performed by molecular docking simulations. 
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Estrogen receptors are a group of proteins that 
are activated by estrogen hormones (17β-
estradiol) (Dahlman et al., 2006). The MCF-7 
cell lines have characterized as expressing 
ERα or proliferate in response to estradiol 
(Gross & Yee, 2002).  
In this paper, the in silico study of 
isolated compounds is carried out to determine 
the stereoselective and regioselective factors 
on the target receptor. The parameters 
observed are the binding affinity and the 
residues binding of ERα. The bond energy or 
binding affinity (ΔG) used to measure as to 
rank order hits binding to the target and help 
design drugs that bind their targets selectively 
and specifically . The smaller or more 
negative ΔG value represents, the stronger 
stability and strength of the bond are (Gupta et 
al., 2015). 
The analysis of result as shown in 
Table 1 presented the interaction of isolated 
compounds with the ligand-binding domain 
(LBD) of the estrogen receptor alpha (ERα). 
This reveals the strength of an interaction 
between each compounds and ERα that is able 
to be observed from the relative binding 
affinity (RBA). 
Molecular docking was carried out on 
the ERα and 4-OHT structures to validate the 
molecular docking method used. The best 
molecular docking results were obtained with 
an RMSD (root mean square deviation) value 
of 0.987 Å from the previous position 




Figure 2. The result of molecular docking on the 4-
OHT ligand with an RMSD value of 0.987 Å. 










Figure 3. Binding site on ERα for: (a) Estradiol (b) 
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From 100 runs, it was obtained one 
cluster with an average binding energy value 
of -11.53 kcal/mol. Molecular docking shows 
the presence of four hydrogen bond 
interactions between 4-OHT and Arg394, 
Glu353, Asp351, TRP383, as well as 
hydrophobic interactions with ALA350, 
LEU346, MET388, LEU387, MET421, 
LEU525 (Figure 3 (3a) and Figure 4). 
Molecular docking is also carried out 
using a natural ligand from ERα, namely 
estradiol. This ligand is obtained from a 
crystalline structure. Molecular tethering is 
carried out using the same protocol as before. 
The result of molecular docking showed ΔG 
value of -9.0 kcal/mol. From the best results, 
two hydrogen bonding interactions were 
obtained with HIS524 and GLY521 and 6 
hydrophobic interactions with LEU346, 
LEU387, LEU525, MET343, MET421 and 
ALA350 (Figure S2 (2b)). 
Molecular docking on the ERα with 
compound 1 and 2 showed free energy -8.8 
kcal/mol and -8.7 kcal/mol respectively. Based 
on this data, compound 1 and 2 have 
molecular mechanism to inhibit ERα in breast 
cancer cells which is shown through the 
formation of hydrogen bonds with ERα. 
Moreover, compound 1 and 2 attaches the 
same residues with positive controls, 4-OHT, 
in ER-α (Ala350 and Leu525 residues) (Table 
1 and Figure 3). 
Figure 5 shows the bioavailability radar 
of molecules. The bioavailability radar gives a 
main scan at the drug-likeness of a compound. 
All the compounds passed the drug-likeliness 
test as shown in Table 2; they also passed the 
Lipinski rule of five, a criteria used as a guide 
in drug design (the molecules that adhere to 
three rules out of the four rules are said to 









Figure 4. The 2D binding site on ERα for 
compound 1 (a) compound 2 (b) 
  
Tabel 1. Attached residues to ligands 
 
Residues binding at ligand-protein complex 
Ligands ERα 
4-OHT Arg394, Glu353, Met421, Ala350, Leu387, Leu346, Leu525, Met388, Asp351, and Trp383 
Estradiol Gly521, His524, Met421, Leu346, Met343, Leu387, Leu525 and Ala350 
1 Thr347, Ala350, Leu525, and Leu536 
2 Thr347, Ala350, Leu525, and Trp383 
 
 
Table 2. Pharmacokinetics properties 
 
Compound MW (g/mol) Log P TPSA (Ǻ
2
) HBA HBD Rule of 5 violation 
Kokosanolid A 500.54 2.41 121.50 9 1 1 
Kokosanolid C 48.55 3.05 104.43 8 1 0 
 










Figure 5. The bioavailibility radar for: compound 
Compound 1 (a) Compound 2 (b) 
 
 
4. CONCLUSIONS  
Two tetranortriterpenoids, 
kokosanolide A (1) and kokosanolide C (2) 
showed strong bond-free energy (-8.8 
kcal/mol and -8.7 kcal/mol) to ERα. These 
two compounds have a molecular mechanism 
to inhibit ERα in breast cancer cells.   
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